LifeStance Health Group (NASDAQ:LFST) Posts Earnings Results, Beats Expectations By $0.03 EPS

LifeStance Health Group (NASDAQ:LFST) announced its quarterly earnings results on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03, FiscalAI reports. The business had revenue of $435.35 million during the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The firm’s revenue was up 26.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.01) EPS.

Here are the key takeaways from LifeStance Health Group’s conference call:

• Positive Sentiment: LifeStance reported strong second-quarter performance, with revenue up 26% to $435 million, visits rising 19% to 2.6 million, and Adjusted EBITDA nearly doubling to $66 million. Adjusted EBITDA margin reached 15.2%, up more than 500 basis points year over year.
• Positive Sentiment: Management raised full-year 2026 guidance, now projecting revenue of $1.685 billion-$1.725 billion and Adjusted EBITDA of $215 million-$235 million. The midpoint implies 20% revenue growth and a 13.2% Adjusted EBITDA margin.
• Positive Sentiment: Clinician additions and productivity remain key growth drivers, with 193 net clinicians added in the quarter to reach 8,542, while visits per average clinician increased 7% for the third consecutive quarter. Management said only about 70% of clinician-provided capacity is currently being utilized, indicating further runway.
• Positive Sentiment: Specialty services, including TMS and SPRAVATO, are expanding and generated roughly $50 million of revenue last year, with expected growth of about 40% in 2026. The company also sees significant opportunity from geographic expansion, tuck-in acquisitions, AI-enabled tools, and a planned 2027 EHR rollout.
• Negative Sentiment: Third-quarter Adjusted EBITDA guidance of $49 million-$59 million implies a sequential decline as LifeStance increases spending on technology, patient acquisition, clinical excellence, compensation, and support staff. Management also cautioned that the phased EHR implementation could cause a temporary productivity dip.

LifeStance Health Group Stock Performance

LifeStance Health Group stock traded up $0.18 during trading hours on Friday, reaching $10.84. 3,793,084 shares of the company were exchanged, compared to its average volume of 3,253,660. LifeStance Health Group has a 12 month low of $3.90 and a 12 month high of $11.76. The company has a current ratio of 1.38, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. The stock has a 50-day moving average of $9.95 and a 200 day moving average of $8.05. The firm has a market cap of $4.20 billion, a price-to-earnings ratio of 83.39 and a beta of 1.14.

More LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: BTIG raises price target: BTIG Research raised its LFST price target from $15 to $16 and initiated a “buy” rating, implying substantial potential appreciation from the referenced $10.84 price. Benzinga price target report
• Positive Sentiment: Q2 earnings beat expectations: LifeStance reported adjusted earnings of $0.06 per share, exceeding the $0.03 consensus estimate, compared with a $0.01 loss in the year-earlier quarter. Revenue rose 26.1% year over year to approximately $435.4 million, ahead of the $414.6 million analyst forecast. LifeStance Q2 earnings report
• Positive Sentiment: Profitability improved sharply: Net income reached $23.6 million versus a $3.8 million loss a year ago, while adjusted EBITDA nearly doubled to $66.0 million. Visit volume increased 19% and the clinician base grew 11% to 8,542, supporting the company’s growth outlook. LifeStance financial results release
• Positive Sentiment: Full-year outlook raised: Management increased 2026 revenue guidance to $1.685 billion-$1.725 billion, Center Margin guidance to $570 million-$594 million and adjusted EBITDA guidance to $215 million-$235 million. Third-quarter revenue is projected at $420 million-$440 million, above the $417.7 million consensus estimate.
• Positive Sentiment: Share repurchase authorization: The board approved a new program allowing up to $100 million of common-stock repurchases, potentially supporting per-share results and signaling management confidence in the company’s valuation.
• Neutral Sentiment: Balance-sheet considerations: LifeStance generated $99.9 million of operating cash flow in Q2 and ended the period with $225.9 million in cash, but reported $259.0 million of net long-term debt.
• Negative Sentiment: Insider selling remains a risk: Recent disclosed insider activity has consisted entirely of sales, including substantial transactions by TPG-related entities and company executives. Continued selling could temper investor enthusiasm despite the strong operating results.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on LFST. Canaccord Genuity Group increased their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. BTIG Research lifted their target price on shares of LifeStance Health Group from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Friday. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. KeyCorp increased their price target on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.62.

Insider Buying and Selling at LifeStance Health Group

In related news, Director Robert Bessler sold 894,337 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the sale, the director owned 539,763 shares in the company, valued at approximately $5,467,799.19. This trade represents a 62.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Darren M. Black sold 5,899,661 shares of LifeStance Health Group stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $47,315,281.22. Following the sale, the director directly owned 23,310,115 shares in the company, valued at $186,947,122.30. The trade was a 20.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 7,612,394 shares of company stock worth $62,938,451 over the last ninety days. Company insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of LFST. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of LifeStance Health Group by 62.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after purchasing an additional 1,839,465 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in LifeStance Health Group by 27.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after purchasing an additional 1,790,694 shares during the period. Integral Health Asset Management LLC boosted its stake in shares of LifeStance Health Group by 100.0% in the 4th quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock valued at $21,120,000 after purchasing an additional 1,500,000 shares during the last quarter. Barclays PLC grew its position in shares of LifeStance Health Group by 74.7% during the 3rd quarter. Barclays PLC now owns 3,508,552 shares of the company’s stock worth $19,297,000 after buying an additional 1,499,687 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of LifeStance Health Group during the 3rd quarter worth approximately $7,637,000. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.